COVAX aims to resolve Venezuela COVID-19 vaccine roadblocks after Maduro ‘ultimatum’

CARACAS (Reuters) – The COVAX vaccine-sharing facility is aiming to overcome roadblocks to the shipment of coronavirus shots to Venezuela “as soon as possible,” a spokesman for the GAVI alliance said on Tuesday.

The comments from GAVI, the Vaccine Alliance which runs COVAX with the World Health Organization, came after President Nicolas Maduro on Sunday said he was giving the COVAX system an “ultimatum” to send doses to the crisis-stricken South American country or return the money Venezuela had already paid.

Officials from the OPEC nation said in June that several payments to cover the $120 million fee have been made, but that the final four payments have been blocked by Swiss bank UBS. Maduro’s allies have attributed that to U.S. sanctions aimed at ousting him from the presidency.

“We are working to resolve this matter as quickly as possible,” a GAVI spokesperson said.

Washington in 2019 blacklisted Venezuela’s state oil company, central bank and other government institutions, though it exempts humanitarian transactions from the sanctions.

Still, the measures have left many banks wary of processing even authorized Venezuela-related transactions.

Venezuela’s COVAX payments are not subject to any sanctions, but pose compliance problems for UBS because the government has not satisfactorily spelled out to the bank exactly what the payment is for, a person familiar with the matter said, adding that UBS will execute the transaction as soon as the open questions are clarified.

Venezuela’s information ministry did not immediately respond to a request for comment.

Several of the payments to COVAX were made by local Venezuelan banks on the government’s behalf, Reuters reported last month.

Venezuela has received 3.5 million vaccine doses from allies Russia and China, and is also conducting trials for Cuba’s Abdala vaccine.

(Reporting by Mayela Armas and Michael Shields; Writing by Luc Cohen; Editing by Bill Berkrot)

Exclusive: WHO estimates COVID-19 boosters needed yearly for most vulnerable

By Francesco Guarascio

BRUSSELS (Reuters) – The World Health Organization (WHO) forecasts that people most vulnerable to COVID-19, such as the elderly, will need to get an annual vaccine booster to be protected against variants, an internal document seen by Reuters shows.

The estimate is included in a report, which is to be discussed on Thursday at a board meeting of Gavi, a vaccine alliance that co-leads the WHO’s COVID-19 vaccine program COVAX. The forecast is subject to changes and is also paired with two other less likely scenarios.

Vaccine makers Moderna Inc and Pfizer Inc, with its German partner BioNTech, have been vocal in their view that the world will soon need booster shots to maintain high levels of immunity, but the evidence for this is still unclear.

The document shows that the WHO considers annual boosters for high-risk individuals as its “indicative” baseline scenario, and boosters every two years for the general population.

It does not say how these conclusions were reached, but shows that under the base scenario new variants would continue to emerge and vaccines would be regularly updated to meet these threats.

The U.N. agency declined to comment on the content of the internal document while Gavi did not immediately respond to a request for comment.

The document, which is dated June 8 and is still “work in progress,” also predicts under the base case that 12 billion COVID-19 vaccine doses will be produced globally next year.

That would be slightly higher than the forecast of 11 billion doses for this year cited by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), signaling that the U.N. agency does not expect a significant ramp-up of vaccine production in 2022.

The document predicts manufacturing problems, regulatory approval issues and “transition away from some technology platforms” as potential drags on supplies next year.

It does not signal which technologies could be phased out, but the European Union, which has reserved the world’s largest volume of COVID-19 vaccines, has bet heavily on shots using messenger RNA (mRNA) technology, such as those by Pfizer and Moderna, and has forgone some purchases of viral vector vaccines from AstraZeneca and Johnson & Johnson.

WORST-CASE SCENARIO

The scenarios will be used to define the WHO’s global vaccination strategy and the forecasts may change as new data emerge on the role of boosters and the duration of vaccine protection, Gavi says in another document, also seen by Reuters.

So far about 2.5 billion doses have been administered worldwide, mostly in rich countries where over half of the population has received at least one dose, whereas in many poorer countries less than 1% has been vaccinated, according to Gavi’s estimates.

This gap could widen next year under the WHO’s most pessimistic forecast, as the need for annual boosters could push once again poorer nations to the back of the queue.

In its worst-case scenario, the U.N. agency says production would be 6 billion doses next year, due to stringent regulation for new shots and manufacturing issues with existing ones.

That could be compounded by the need for annual boosters for the entire world, and not just the most vulnerable, to combat variants and limited duration of protection.

In the more optimistic situation, all vaccines in the pipeline would get authorized and production capacity would ramp up to about 16 billion doses to meet demand. Vaccines would also be shared equitably across the world.

There would be no need for boosters as vaccines would show strong efficacy against variants and long protection.

(Reporting by Francesco Guarascio @fraguarascio; Editing by Josephine Mason and Emelia Sithole-Matarise)

Biden says biggest vaccine donation ‘supercharges’ battle against coronavirus

By Steve Holland

CARBIS BAY, England (Reuters) – U.S. President Joe Biden said on Thursday that a donation of 500 million doses of the Pfizer COVID-19 vaccine to the world’s poorest countries would supercharge the battle with the virus and comes with “no strings attached.”

Biden, speaking alongside Pfizer Chief Executive Albert Bourla in the English seaside resort of Carbis Bay ahead of a G7 summit, thanked other leaders for recognizing their responsibility to vaccinate the world.

“The United States is providing these half billion doses with no strings attached. No strings attached,” Biden said. “Our vaccine donations don’t include pressure for favors, or potential concessions. We’re doing this to save lives.”

Biden, keen to burnish his multilateral credentials on his first foreign trip as leader, cast the donation as a bold move that showed America recognized its responsibility to the world and to its own citizens.

“America will be the arsenal of vaccines in our fight against COVID-19, just as America was the arsenal of democracy during World War Two,” Biden said.

The largest ever vaccine donation by a single country will cost the United States $3.5 billion but will spur further donations from other G7 leaders – including British Prime Minister Boris Johnson.

G7 leaders want to vaccinate the world by the end of 2022 to try to halt the COVID-19 pandemic that has killed more than 3.9 million people, devastated the global economy and upended the normal lives of billions of people.

Vaccination efforts so far are heavily correlated with wealth: the United States, Europe, Israel and Bahrain are far ahead of other countries. A total of 2.2 billion people have been vaccinated so far out of a world population of nearly 8 billion, based on Johns Hopkins University data.

‘SAVE LIVES’

U.S. drugmaker Pfizer and its German partner BioNTech have agreed to supply the U.S. with the vaccines, delivering 200 million doses in 2021 and 300 million doses in the first half of 2022.

The shots, which will be produced at Pfizer’s U.S. sites, will be supplied at a not-for-profit price. Around 100 countries will get the shots.

Pfizer CEO Bourla said the eyes of the world were on the leaders of rich nations to see if they would act to solve the COVID-19 crisis and share with poorer nations.

“This announcement with the U.S. government gets us closer to our goal and significantly enhances our ability to save even more lives across the globe,” he said.

While such a large donation of vaccines was welcomed by many, there were immediately calls for the richest nations of the world to open up more of their giant hoards of vaccines.

Anti-poverty campaign group Oxfam called for more to be done to increase global production of vaccines.

“Surely, these 500 million vaccine doses are welcome as they will help more than 250 million people, but that’s still a drop in the bucket compared to the need across the world,” said Niko Lusiani, Oxfam America’s vaccine lead.

“We need a transformation toward more distributed vaccine manufacturing so that qualified producers worldwide can produce billions more low-cost doses on their own terms, without intellectual property constraints,” he said in a statement.

Another issue, especially in some poor countries, is the infrastructure for transporting the vaccines which often have to be stored at very cold temperatures.

IP WAIVER

Biden has also backed calls for a waiver of some vaccine intellectual property rights but there is no international consensus yet on how to proceed.

The new vaccine donations come on top of 80 million doses Washington has already pledged to donate by the end of June. There is also $2 billion in funding earmarked for the COVAX program led by the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI), the White House said.

GAVI and the WHO welcomed the initiative.

Washington is also taking steps to support local production of COVID-19 vaccines in other countries, including through its Quad initiative with Japan, India and Australia.

(Reporting by Steve Holland in St. Ives, England, Andrea Shalal in Washington and Caroline Copley in Berlin; Writing by Guy Faulconbridge and Keith Weir; Editing by Leslie Adler, David Evans, Emelia Sithole-Matarise, Giles Elgood, Jane Merriman and Marguerita Choy)

COVID fight could return ‘to square one’: experts sound vaccines alarm

By Kate Kelland

LONDON (Reuters) – India’s export ban on COVID-19 shots risks dragging the battle against the pandemic “back to square one” unless wealthy nations step in to plug a gaping hole in the COVAX global vaccine-sharing scheme, health specialists said on Thursday.

COVAX, which is critical for poorer countries, relies on AstraZeneca shots made by the Serum Institute of India, the world’s biggest maker of vaccines. It was already around 100 million doses short of where it had planned to be when India halted exports a month ago amid a surge in infections there.

Rich countries with plentiful COVID-19 vaccine stocks must now share them immediately, at scale, the global experts said, otherwise the pandemic could be prolonged as the world struggles to contain a virus that is continuing to spread and mutate.

“It is a huge concern,” said Anna Marriott, health policy manager at the global charity Oxfam. She and others said it was imperative that wealthy countries and regions make good on their rhetoric and share excess vaccines now.

“The current approach that relies on a few pharma monopolies and a trickle of charity through COVAX is failing – and people are dying as a result.”

Reuters reported on Tuesday that India is extending its ban, meaning it is now unlikely to resume major exports before October.

Will Hall, global policy manager for the Wellcome global health trust, said COVAX’s heavy reliance on the Serum Institute left it vulnerable. India’s extension of its export ban made it even more crucial for rich countries to share doses via the scheme, he said, “not in six months’ time, not in a month’s time, but now”.

“We’re not going to beat this virus unless we think and act globally,” he added. “We all should be concerned about this – the more the virus continues to spread, the greater the risk of it mutating to a stage where our vaccines and treatments no longer work. If that happens we’re back to square one.”

A highly transmissible new variant of the novel coronavirus first identified in India has spread to several countries around the world.

‘VERY FEW OPTIONS’

COVAX aims to get vaccines to at least 20% of the populations of the more-than 90 low and middle-income countries signed up to receive the shots as donations. It has so far distributed about 65 million doses of mainly the AstraZeneca COVID-19 vaccine, many of them to Africa.

A spokeswoman for the GAVI vaccines alliance, which co-leads COVAX, said the facility was working hard to make up supplies.

“We’re trying to find different ways of making sure that those countries that have received the first dose are able to also receive a second dose and that vaccinations can continue,” she told Reuters. “What we need right now, to meet the immediate needs, is dose sharing.”

The United States said on Wednesday it would share a total of 20 million doses of Pfizer’s, Moderna’s and Johnson & Johnson’s vaccines by the end of June, donating a significant amount via COVAX, on top of 60 million AstraZeneca shots it had already planned to give to other countries.

EU trade commissioner Valdis Dombrovskis said this week that the bloc was working to significantly ramp up vaccine donations through COVAX in the second half of 2021. Vaccine sharing announced by EU member states has so far amounted to 11.1 million vaccines, he said, of which 9 million are being shared via COVAX.

Britain, meanwhile, will have enough surplus doses to fully vaccinate at least 50 million people in poorer countries once every adult at home has been fully vaccinated, according to analysis by UNICEF’s UK office last week.

The GAVI spokeswoman said COVAX’S reliance on the Serum Institute was based, largely, on its vast production capacity, ability to deliver at low cost and on assurances that it would be able to produce the millions of doses needed at speed.

“It always was COVAX’s plan to grow and diversify its portfolio to 10-12 vaccines but at the start of the year when approved vaccines were only slowly coming online, we had very few options available to us,” she said.

(Reporting by Kate Kelland; Additional reporting by Francesco Guarascio in Brussels and Ludwig Burger in Frankfurt; Editing by Pravin Char)

Measles surging as COVID-19 curbs disrupt vaccinations

By Kate Kelland

LONDON (Reuters) – Measles surged to infect almost 870,000 people across the world in 2019, the worst figures in almost a quarter of a century as vaccination levels fell below critical levels, a report said on Thursday.

Millions of children are at risk of the disease again this year as restrictions imposed to contain the COVID-19 pandemic further disrupt immunization programs, the report co-led by the World Health Organization (WHO) said.

Measles is one of the most contagious known diseases – more so than COVID-19, Ebola, tuberculosis or flu.

More than 207,000 people died of it last year alone, the report found. With immunization coverage below the critical 95% needed for community protection, infections rose in all WHO regions last year to the worst levels since 1996, it said.

“These data send a clear message that we are failing to protect children from measles in every region of the world,” the WHO’s Director-General, Tedros Adhanom Ghebreyesus, said in a statement.

The surge in fatal cases means global measles deaths have risen nearly 50% since 2016.

The report, co-led by the United States Centers for Disease Control and Prevention (CDC), cited a collective failure to fully immunize children on time with two doses of measles vaccine as the main driver of the deadly increases.

Looking ahead to 2020, the report warned that disruptions to vaccination due to the COVID-19 pandemic have crippled efforts to curb measles outbreaks.

As of this month, more than 94 million people were at risk of missing measles vaccinations due to paused immunization campaigns in 26 countries, it said.

“COVID-19 has resulted in dangerous declines in immunization coverage,” Seth Berkley, chief executive of the GAVI global vaccine alliance, said.

He described the “alarming” measles report was “a warning that, with the COVID-19 pandemic occupying health systems across the world, we cannot afford to take our eye off the ball.”

After steady downward progress from 2010 to 2016, measles cases began rising again from 2017. The report said there were a total of 869,770 measles cases, with 207,500 deaths, in 2019.

WHO and the UN children’s fund UNICEF urged governments last week to act now to prevent epidemics of measles, polio and other infectious diseases.

(Reporting by Kate Kelland, editing by Andrew Heavens)

U.N. chief: time for national plans to help fund global COVID-19 vaccine effort

By Michelle Nichols and Stephanie Nebehay

NEW YORK/GENEVA (Reuters) – U.N. chief Antonio Guterres said on Wednesday it is time for countries to start using money from their national COVID-19 response to help fund a global vaccine plan as the World Bank warned that “broad, rapid and affordable access” to those doses will be at the core of a resilient global economic recovery.

The Access to COVID-19 Tools (ACT) Accelerator and its COVAX facility – led by the World Health Organization and GAVI vaccine alliance – has received $3 billion, but needs another $35 billion. It aims to deliver 2 billion vaccine doses by the end of 2021, 245 million treatments and 500 million tests.

At a high-level virtual U.N. event on the program, WHO chief Tedros Adhanom Ghebreyesus said the financing gap was less than 1% of what the world’s 20 largest economies (G20) had committed to domestic stimulus packages and “it’s roughly equivalent to what the world spends on cigarettes every two weeks.”

German Chancellor Angela Merkel pledged $100 million to GAVI to help poorer countries gain access to a vaccine and Johnson & Johnson Chief Executive Alex Gorsky committed 500 million vaccine doses for low-income countries with delivery starting in mid-2021.

“Having access to lifesaving COVID diagnostics, therapeutics or vaccines … shouldn’t depend on where you live, whether you’re rich or poor,” said Gorsky, adding that while Johnson & Johnson is “acting at an unprecedented scale and speed, but we are not for a minute cutting corners on safety.”

U.S. President Donald Trump has said that a vaccine against the virus might be ready before the Nov. 3 U.S. presidential election, raising questions about whether political pressure might result in the deployment of a vaccine before it is safe.

“We remain 100 percent committed to high ethical and scientific principles,” Gorsky said.

GAVI Chief Executive Seth Berkley said that so far 168 countries, including 76 self-financing states, have joined the COVAX global vaccines facility. Tedros said this represented 70% of the world’s population, adding: “The list is growing every day.”

China, Russia and the United States have not joined the facility, although WHO officials have said they are still holding talks with China about signing up. The United States has reached its own deals with vaccine developers.

‘LONG HAUL’

World Bank President David Malpass said the pandemic could push 150 million people into extreme poverty by 2021 and the “negative impact on human capital will be deep and may last decades.”

“Broad, rapid and affordable access to COVID vaccines will be at the core of a resilient global economic recovery that lifts everyone,” he said.

Guterres said that the ACT-Accelerator was the only safe and certain way to reopen the global economy quickly.

But he warned that the program needed an immediate injection of $15 billion to “avoid losing the window of opportunity” for advance purchase and production, to build stocks in parallel with licensing, boost research, and help countries prepare.

“We cannot allow a lag in access to further widen already vast inequalities,” Guterres said.

“But let’s be clear: We will not get there with donors simply allocating resources only from the Official Development Assistance budget,” he said. “It is time for countries to draw funding from their own response and recovery programs.”

U.N. Secretary-General Guterres called on all countries to step up significantly in the next three months.

Billionaire Bill Gates told the U.N. event that the Bill & Melinda Gates Foundation had signed an agreement with 16 pharmaceutical companies on Wednesday.

“In this agreement the companies commit to, among other things, scaling up manufacturing, at an unprecedented speed, and making sure that approved vaccines reach broad distribution as early as possible,” Gates said.

Britain’s Foreign Secretary Dominic Raab – a co-host of the meeting along with Guterres, the WHO and South Africa – urged other countries to join the global effort, saying the ACT-Accelerator is the best hope of bringing the pandemic under control.

Said Merkel: “We’re in for the long haul and we need more support.”

(Reporting by Michelle Nichols and Stephanie Nebehay; Editing by Chizu Nomiyama, Paul Simao and Jonathan Oatis)

Latin American nations seek more time to join WHO vaccine plan

By Anthony Boadle

BRASILIA (Reuters) – Several Latin American countries have informed the World Health Organization (WHO) they intend to request more time to sign up for its global COVID-19 vaccine allocation plan known as COVAX, an official at the WHO’s regional branch said on Thursday.

Countries have until midnight on Friday to formalize legally binding commitments to COVAX, a mechanism for pooled procurement and equitable distribution of eventual vaccines.

A representative for the GAVI Alliance, the COVAX secretariat, said by email that details of which nations have joined COVAX will only be made public after the deadline.

Health officials in Mexico, which has the worst outbreak in Latin America after Brazil, said their country would sign the commitment on time. Brazil, which has the world’s most severe outbreak outside the United States and India, was still studying what to do, a ministry spokesperson said.

More than 170 countries have joined the global vaccine plan to help buy and distribute immunization shots for COVID-19 fairly around the world, WHO’s director general Tedros Adhanom Ghebreyesus said on Thursday.

Jarbas Barbosa, assistant director of the Pan-American Health Organization, said in a briefing on Wednesday that Latin American countries were having trouble meeting the deadline and some wanted to push back the date.

Barbosa said all countries in the Americas except the United States had expressed interest in the vaccine facility, even those that have separate agreements with vaccine makers, because it gives them an added guarantee of access to doses.

Ten Latin American countries are among 90 poor nations in the world that will not have to pay for the vaccine, while the others in the region will pay an “accessible” price through COVAX, Barbosa said.

Colombian President Ivan Duque confirmed on Wednesday that his government was joining COVAX and Paraguay’s health ministry said it has already signed, even as it plans to buy the vaccine being developed by AstraZeneca PLC and Oxford University.

(Reporting by Anthony Boadle in Brasilia, Diego Ore in Mexico City, Julia Cobb in Bogotá, Daniela Desantis in Asunción; Editing by Daniel Flynn and Chizu Nomiyama)

WHO’s Tedros says ‘vaccine nationalism’ would prolong pandemic

By Stephanie Nebehay and Emma Farge

GENEVA (Reuters) – WHO Director-General Tedros Adhanom Ghebreyesus said on Friday that “vaccine nationalism” would only slow the effort to quash the pandemic and called for vaccines to be used fairly and effectively.

Tedros said 78 high-income countries had now joined the “COVAX” global vaccine allocation plan, bringing the total to 170 countries, and the “number is growing”. He urged others to join by the Sept. 18 deadline for binding commitments.

Joining the plan guaranteed those countries access to the world’s largest portfolio of vaccines, with nine candidates currently in the pipeline, he said, adding that a further four were “promising”.

The WHO and the GAVI vaccine alliance are leading the COVAX facility, aimed at helping buy and distribute vaccination shots fairly around the world.

But some countries that have secured their own supplies through bilateral deals, including the United States, have said they will not join COVAX.

“Vaccine nationalism will prolong the pandemic, not shorten it,” Tedros told a WHO briefing in Geneva, without mentioning any specific countries.

“If and when we have an effective vaccine, we must also use it effectively … In other words, the first priority must be to vaccinate some people in all countries, rather than all people in some countries,” he said, adding that priority should be given to healthcare workers, the elderly and those with underlying conditions.

Tedros thanked Germany, Japan, Norway and the European Commission for joining COVAX during the last week.

“Certainly by the middle of 2021 we should start to see some vaccines actually moving into countries and populations,” said WHO chief scientist Soumya Swaminathan, reiterating earlier comments.

Noting that there were 13 experimental vaccines currently in clinical trails, Swaminathan called it an “optimistic scenario” since the typical success rate of 10% could mean several vaccines are approved.

But Swaminathan said that no vaccine should be approved for a worldwide rollout until it had undergone sufficient scrutiny.

“No vaccine is going to be mass-deployed until regulators are confident, governments are confident, and the WHO is confident it has met the minimum standard of safety and efficacy,” she said.

Results were expected from some of the candidates already in phase 3 trials, each involving thousands of participants, by the end of the year or early 2021, Swaminathan said.

“We are not going to have enough for the whole world right at the beginning,” she said adding that scaling up of manufacturing would take time.

“Eventually there will be enough for everyone but it will mean prioritization,” she said.

(Reporting by Stephanie Nebehay and Emma Farge; Editing by Alison Williams and Giles Elgood)

Widespread COVID-19 vaccinations not expected until mid-2021, WHO says

By Stephanie Nebehay and Emma Farge

GENEVA (Reuters) – The World Health Organization does not expect widespread vaccinations against COVID-19 until the middle of next year, a spokeswoman said on Friday, stressing the importance of rigorous checks on their effectiveness and safety.

None of the candidate vaccines in advanced clinical trials so far has demonstrated a “clear signal” of efficacy at the level of at least 50% sought by the WHO, spokeswoman Margaret Harris said.

Russia granted regulatory approval to a COVID-19 vaccine in August after less than two months of human testing, prompting some Western experts to question its safety and efficacy.

U.S. public health officials and Pfizer Inc said on Thursday a vaccine could be ready for distribution as soon as late October. That would be just ahead of the U.S. election on Nov. 3 in which the pandemic is likely to be a major factor among voters deciding whether President Donald Trump wins a second term.

“We are really not expecting to see widespread vaccination until the middle of next year,” Harris told a U.N. briefing in Geneva.

“This phase 3 must take longer because we need to see how truly protective the vaccine is and we also need to see how safe it is,” she added. This referred to the phase in vaccine research where large clinical trials among people are conducted. Harris did not refer to any specific vaccine candidate.

All data from trials must be shared and compared, Harris said. “A lot of people have been vaccinated and what we don’t know is whether the vaccine works…at this stage we do not have the clear signal of whether or not it has the level of worthwhile efficacy and safety…,” she added.

The WHO and GAVI vaccine alliance are leading a global vaccine allocation plan known as COVAX that aims to help buy and distribute shots fairly. The focus is on first vaccinating the most high-risk people in every country such as healthcare workers.

COVAX aims to procure and deliver 2 billion doses of approved vaccines by the end of 2021, but some countries that have secured their own supplies through bilateral deals, including the United States, have said they will not join.

“Essentially, the door is open. We are open. What the COVAX is about is making sure everybody on the planet will get access to the vaccines,” Harris said.

(Reporting by Stephanie Nebehay and Emma Farge; Editing by Frances Kerry)

Exclusive: Vaccine group says 76 rich countries now committed to ‘COVAX’ access plan

By Kate Kelland

LONDON (Reuters) – Seventy-six wealthy nations are now committed to joining a global COVID-19 vaccine allocation plan co-led by the World Health Organization (WHO) that aims to help buy and fairly distribute the shots, the project’s co-lead said on Wednesday.

Seth Berkley, chief executive of the GAVI vaccines alliance, said the plan, known as COVAX, now has Japan, Germany, Norway and more than 70 other nations signed up, agreeing in principle to procure COVID-19 vaccines through the facility for their populations.

“We have, as of right now, 76 upper middle income and high income countries that have submitted confirmations of intent to participate – and we expect that number to go up,” Berkley told Reuters in an interview.

“This is good news. It shows that the COVAX facility is open for business and is attracting the type of interest across the world we had hoped it would.”. COVAX coordinators are in talks with China about whether it might also join, Berkley said.

“We had a discussion yesterday with the (Chinese) government. We don’t have any signed agreement with them yet,” but Beijing had given “a positive signal”.

Chinese Foreign Ministry spokeswoman Hua Chunying told a briefing on Wednesday that China “supports COVAX and has been in communication with WHO and other parties” about it.

COVAX is co-led by GAVI, the WHO and the Coalition for Epidemic Preparedness Innovations (CEPI). It is designed to discourage national governments from hoarding COVID-19 vaccines and to focus on first vaccinating the most high-risk people in every country.

Its backers say this strategy should lead to lower vaccine costs for everyone and a swifter end to the pandemic that has claimed some 860,000 lives globally.

Wealthy countries that join COVAX will finance the vaccine purchases from their national budgets, and will partner with 92 poorer nations supported through voluntary donations to the plan to ensure vaccines are delivered equitably, Berkley said.

Participating wealthy countries are also free to procure vaccines through bilateral deals and other plans.

The United States said on Tuesday it would not join COVAX due to the Trump administration’s objection to WHO involvement, a move described by some critics as “disappointing.” Berkley said he was not surprised by the U.S. decision, but would seek to continue talks with Washington.

In what appeared to be a change of position on Wednesday, the European Union said its member states could buy potential COVID-19 vaccines through COVAX.

COVAX coordinators sought to add flexibility to joining agreements to encourage greater participation, Berkley said.

The WHO describes COVAX as an “invaluable insurance policy” for all countries to secure access to safe and effective COVID-19 vaccines when they are developed and approved. The plan’s coordinators have set a deadline of Sept. 18 for countries signing up to make binding commitments.

Asked to comment on the U.S. decision not to join COVAX, and on talks with China, a WHO spokesperson said: “Countries have until Sept. 18 to sign binding agreements…, so we’ll have more to say on countries that have joined then.”

COVAX’s objective is to procure and deliver 2 billion doses of approved vaccines by the end of 2021. It currently has nine COVID-19 vaccine candidates in its portfolio employing a range of different technologies and scientific approaches.

A handful are already in late-stage clinical trials and could have data available by year end.

(Reporting by Kate Kelland; Additional reporting by Stephanie Nebehay in Geneva and Yew Lun Tian in Beijing; Editing by Bill Berkrot and Mark Heinrich)